Rhode Island Child Clinical Trials Collaborative

Hasbro儿童医院的罗得岛儿童临床试验协作组织（RI-CCTC），妇女和婴儿 医院和布朗大学，是ECHO ISPCTN的理想临床中心。我们将在成功的基础上再接再厉 在最初的奖励期间，我们是一个顶级的招募网站，开发了一种新的网络新生儿阿片类药物， 退出试验协议，并通过我们的委员会工作为网络提供领导。我们州的 人口统计包括许多服务不足的少数民族和移民儿童，他们的婴儿死亡率很高。 死亡率、哮喘、肥胖、早产、心理健康问题和特殊保健需要。该高风险 许多临床研究中以前没有纳入这一人群，因此直接受益， 从RI-CTC的工作中间接获得。罗得岛是独特的组织为人口为基础的临床研究： 它有一家主要的产科医院（占该州所有分娩的80%），一家儿童医院（占该州所有儿科医院的90%）， 州内的招生）和一个卫生部门，以及一个参与的社区。这些因素考虑到 在临床试验中有效招募、保留和随访研究参与者，使RI-CCTC 有可能产生强大的影响。我们利用我们丰富的合作网络与许多现有的 研究、教育和公共卫生项目，以及与国家研究网络的联系。这些 合作伙伴与我们一样致力于儿童健康和儿童健康研究。布朗大学医学院 公共卫生和阿尔珀特医学院，最近收到了一个大的礼物，以创建哈森菲尔德儿童健康 创新研究所（HCHII），重点是了解产前，围产期和产后因素， 导致儿童哮喘、肥胖和自闭症。RI-CTC将利用HCHII的资源， 一个更广泛和更强大的研究网络，为国际扶轮州的儿童服务。调查人员 公共卫生和医学学院在环境暴露研究方面具有相当的专业知识， 对儿童的影响。联系PI，托马斯春医学博士，公共卫生硕士，具有丰富的多中心经验 通过他在ECHO ISPCTN和儿科急诊的经验， 护理应用研究网络。共同PI Abbot Laptook同样是ISPCTN和NIH的领导者 新生儿研究网络。高级教师发展负责人和共同PI菲利斯登内里医学博士，有 她的基础/转化研究得到了NIH的持续资助，参加了许多培训赠款， 多中心临床试验，并赢得了指导奖。这个团队将确保国际扶轮的持续成功- CCTC在实现ECHO计划的目标和使命中的作用。我们的具体目标是：（1）继续提供 ECHO ISPCTN研究中服务不足患者入组的新机会， 我们的学术研究中心和机构之间的合作; 2）继续提供领导， ECHO ISPCTN和ECHO计划，通过开发新的临床试验和服务于网络委员会; 3)开发和扩大教育和指导临床医生成为独立调查员的计划。

The Rhode Island Child Clinical Trials Collaborative (RI-CCTC) at Hasbro Children's Hospital, Women & Infants Hospital and Brown University, is an ideal clinical center for the ECHO ISPCTN. We will build on our successes in the initial award period, in which we were a top enrolling site, developed a new network neonatal opioid withdrawal trial protocol, and provided leadership to the network through our committee work. Our state's demographic includes many underserved, minority and immigrant children, who have high rates of infant mortality, asthma, obesity, prematurity, mental health problems and special health care needs. This high risk population has not been previously included in many clinical studies, and thus is benefitting both directly and indirectly from the RI-CCTC's work. Rhode Island is uniquely organized for population-based clinical research: it has one major obstetric hospital (80% of all deliveries in the state), one children's hospital (90% of all pediatric admissions in the state) and one health department, as well as an engaged community. These factors allow for effective enrollment, retention and follow-up of study participants in clinical trials, giving the RI-CCTC the potential to make a strong impact. We have leveraged our rich network of collaborations with many existing research, education and public health programs, as well as affiliations with national research networks. These partners share our commitment to children's health and child health research. The Brown University School of Public Health and the Alpert Medical School, recently received a large gift to create the Hassenfeld Child Health Innovation Institute (HCHII), which is focused on understanding the prenatal, perinatal and postnatal factors that lead to childhood asthma, obesity and autism. The RI-CCTC will leverage the resources of the HCHII to create a much broader and more powerful research network to serve children in the state of RI. Investigators in the Schools of Public Health and Medicine have considerable expertise in the study of environmental exposures and their impact on children. The contact PI, Thomas Chun MD, MPH, has extensive experience with multi-center networks and their leadership, through his experience with the ECHO ISPCTN and the Pediatric Emergency Care Applied Research Network. Co-PI Abbot Laptook similarly is a leader in both the ISPCTN and the NIH funded Neonatal Research Network. Senior Faculty Development Leader and co-PI Phyllis Dennery MD, has had consistent NIH funding for her basic/translational research, has participated in many training grants and multicenter clinical trials, and has won mentoring awards. This team will ensure the continued success of the RI- CCTC in fulfilling the goals and mission of the ECHO Program. Our Specific Aims are to: 1) Continue to provide new opportunities for underserved patient enrollment in ECHO ISPCTN studies by building on our current collaborations between our academic research centers and institutions; 2) Continue to provide leadership to the ECHO ISPCTN and ECHO Program by developing new clinical trials and serving on network committees; 3) Develop and expand programs to educate and mentor clinicians to become independent investigators.